Internal Med

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Goldberg, Ronald B, - Will use of these drugs prevent cardiovascular disease?
>Summary: The purpose of this review was to investigate the possibility of thiazolidinedione agents having vasculoprotective effects and if so whether these are associated with the prevention of cardiovascular disease.
Outcomes: The weight of the experimental, subclinical and clinical assessments of the effects of these agents supports the contention that they are vasculoprotective. In the final analysis their use in clinical practice to prevent cardiovascular disease will mostly depend on whether clinical trials consistently demonstrate that they reduced cardiovascular events


Previous Article Next Article

Today in Clinical Pharmacology...keeping you current

Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: A systematic review
Annals of Rheumatic Diseases, 06/09/09

Denosumab update
Current Opinion in Rheumatology, 06/11/09

Dapsone 5 Gel: A Review of its Efficacy and Safety in the Treatment of Acne Vulgaris
American Journal of Clinical Dermatology, 06/09/09

Today in Vascular Medicine...keeping you current

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
The Lancet - Early Online Publication, 06/09/09

Management of hypertension in acute stroke
Expert Review of Cardiovascular Therapy , 06/12/09

Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials
Vascular Health and Risk Management, 05/11/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address